Four analysts set a USD 5.03 target for Outlook Therapeutics stock

Published on 10/24/2026 at 20:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

June net loss reached USD 20.32 million. Outlook Therapeutics stock costs EUR 0.47 on October 24, 2026 at 1:04 p.m. CEST.

Reporting date and valuation

Four analysts set a USD 5.03 average target on October 22, 2026.
Outlook Therapeutics posted a USD 20.32 million net loss for the quarter ended June 30, 2026.
Outlook Therapeutics stock costs EUR 0.47 at Lang & Schwarz on October 24, 2026 at 1:04 p.m. CEST.
Nasdaq's compliance deadline is March 24, 2027.

OTLK, US69012T3059, Illustration mit AI erstellt.

Outlook Therapeutics (US69012T3059) has a USD 5.03 average analyst target based on four analysts, according to Bullstory on October 22, 2026. The target stands against a company whose latest reported quarter ended June 30, 2026 with a net loss of USD 20.32 million, while the stock was trading at EUR 0.47 at Lang & Schwarz on October 24, 2026 at 1:04 p.m. CEST.

The target gap remains wide

The USD 5.03 average target is a consensus figure rather than a single firm's new recommendation. Bullstory reported four analysts in the group and listed a USD 1.60 low target and a USD 10.50 high target on October 22, 2026. The spread underlines how heavily valuation depends on Outlook Therapeutics' commercial execution.

The company is developing and commercializing LYTENAVA, an ophthalmic formulation of bevacizumab for wet age-related macular degeneration. Its investor-relations page describes LYTENAVA as FDA-approved in the United States and authorized in the European Union and United Kingdom.

Losses still shape the valuation

Outlook Therapeutics reported revenue of USD 8,700 and a consolidated net loss of USD 20.32 million for the quarter ended June 30, 2026, according to Business Quant. Operating cash flow was negative USD 21.01 million in the same quarter, adding a financing and launch-execution dimension to the target debate.

Nasdaq deadline is March 24

Outlook Therapeutics received a Nasdaq minimum-bid notice after its shares closed below USD 1.00 for 30 consecutive business days. The company has until March 24, 2027 to regain compliance, as reported by Simply Wall St. The notice does not immediately remove the stock from the Nasdaq Capital Market.

Price and market frame

Primary-market context places the stock at USD 0.52 on Nasdaq after the October 23, 2026 session, with a 52-week range of USD 0.16 to USD 2.54 and market capitalization of USD 126.4 million. Outlook Therapeutics is a biotechnology company with 17 full-time employees, according to company profile information.

For investors, the central tension is measurable: a USD 5.03 average target sits alongside a USD 20.32 million quarterly net loss and negative USD 21.01 million operating cash flow. The next valuation test is the planned commercial progress of LYTENAVA and the Nasdaq deadline.

Stock stays below the dollar threshold

Outlook Therapeutics stock was trading at EUR 0.47 at Lang & Schwarz on October 24, 2026 at 1:04 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Outlook Therapeutics stock.